
FOR IMMEDIATE RELEASE

Eleison Pharmaceuticals Announces Artificial Intelligence Collaboration with BullFrog AI to Optimize Eleison Clinical Development

Princeton, NJ, March 1, 2025 -- Eleison Pharmaceuticals Inc. (“Eleison” or the “Company”), a specialty pharmaceutical company developing life-saving therapeutics for patients with rare cancers and cancers with unmet need, has announced it has entered into a collaboration with BullFrog AI to optimize clinical development of Eleison’s late-stage programs. Under the terms of the agreement, Bullfrog AI will provide access to its BullFrog Data Networks™ AI solution to enhance clinical trial efficiency and patient insights.

“The integration of artificial intelligence in clinical trials represents a transformative shift in how pharmaceutical companies can de-risk drug development and optimize patient outcomes,” said Vin Singh, CEO of BullFrog AI. “We are thrilled to partner with Eleison to apply our bfLEAP® AI technology, which has the potential to refine patient selection, improve trial efficiency, and ultimately accelerate the path to market for life-saving therapies.”

Through this collaboration, BullFrog AI will apply its proprietary BullFrog Data Networks™ solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison’s ongoing Phase 3 trial and previous clinical studies of glufosfamide, an investigational treatment for pancreatic cancer. The platform will evaluate the current trajectory of the trial with respect to safety signals, extract predictive biomarkers for efficacy and safety performance from prior studies to support future trial design, and provide data-driven insights to optimize Eleison’s planned clinical trials for inhaled lipid-complexed cisplatin (ILC) and dibromodulcitol (DBD). These insights are expected to streamline trial efficiency and improve decision-making for Eleison’s broader oncology pipeline.

“Our collaboration with BullFrog AI underscores our commitment to innovation in drug development,” said Edwin Thomas, CEO of Eleison. “By leveraging AI-powered analytics, we aim to generate deeper insights into patient responses and safety trends, which will not only benefit our glufosfamide program but also inform the strategic direction of our broader oncology pipeline.”

Clinical Development Update

Eleison has three programs in late-stage clinical development. Glufosfamide is currently being evaluated in a multi-national phase III clinical trial for patients with relapsed or refractory pancreatic cancer. Although enrollment was slowed by the global pandemic and industry-wide financial pressures, the Company expects enrollment to accelerate in 2025, particularly with the planned expansion of the study to new territories outside the United States. The Company’s ILC (Inhaled Lipid-Cisplatin) program is expected to begin a potentially pivotal phase III clinical trial in 2025 for patients with small cell lung cancer. The Company plans to begin a potentially pivotal phase III study of its DBD (Dibromodulcitol) program for patients with brain cancer in 2026.

About Glufosfamide

Glufosfamide is a third-generation alkylating agent designed for greater specificity and tumor uptake, with reduced systemic toxicities and side effects. It is currently being evaluated in a pivotal phase III international randomized clinical trial, for the second-line treatment of patients with pancreatic cancer. Although pancreatic cancer is among the rarer cancer types, it is the third leading cause of death by cancer in the United States. More than 67,000 Americans and 510,000 people worldwide are diagnosed with pancreatic cancer annually. Few therapeutic options exist to treat the disease and five year survival rates are typically less than 5%. We expect to complete this ongoing phase III trial in 2027.

About ILC

ILC is a novel, sustained release formulation of cisplatin in a nanoscale lipid-based complex administered via inhalation or intraperitoneally. ILC, when administered by inhalation, can deliver

high levels of sustained release cisplatin targeted to the lung, with minimal systemic-related toxicities. Eleison is developing ILC for lung cancer and has also completed a phase II clinical study of ILC in patients with bone cancer (osteosarcoma) metastatic to the lung. We expect to begin a potentially pivotal phase III clinical trial in 2025 or for patients with small cell lung cancer.

About DBD

DBD is an oral cytotoxic agent which crosses the “blood-brain” barrier. It has been evaluated in multiple phase II clinical studies and has shown activity in several cancer types. Eleison intends initially to focus development of DBD for brain cancer. More than 24,000 Americans and 250,000 people worldwide are diagnosed with cancers of the brain and nervous system annually. Approximately 18,000 Americans will die from brain cancer this year according to the American Cancer Society. Few therapeutic options exist to treat the disease and long-term survival is typically very poor.

About Eleison Pharmaceuticals

Eleison’s mission is to acquire and develop drug candidates with existing and significant safety and efficacy data; and ultimately to obtain regulatory approval and commercialize new therapeutics for patients with life-threatening cancers. The Company has three programs in late-stage clinical development and is in discussions to acquire other promising oncology drug candidates. The Company has entered into development and marketing partnerships with leading pharmaceutical companies in China, S. Korea, and Israel. Eleison was founded in 2009 and is headquartered in Princeton, NJ. Additional information about Eleison can be found at our website www.eleison-pharma.com.

About BullFrog AI

BullFrog AI leverages Artificial Intelligence and machine learning to advance drug discovery and development. Through collaborations with leading research institutions, BullFrog AI uses causal AI in combination with its proprietary bfLEAP™ platform to analyze complex biological data, aiming to streamline therapeutics development and reduce failure rates in clinical trials. For more information visit BullFrog AI at: <https://bullfrogai.com>

Forward Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Eleison’s product candidates, their uses and potential benefits and clinical trial plans and results. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Eleison’s ability to enroll and complete its current and anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, the possibility that results from these trials will not be confirmed, potential adverse side effects, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Eleison does not intend to update any forward-looking statement made in this news release.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

SOURCE/CONTACT: Eleison Pharmaceuticals Inc.
Corporate Communications
100 Overlook Center, 2nd Floor
Princeton, NJ 08540
tel : 215-554-3530 email : news@eleison-pharma.com

FOR IMMEDIATE RELEASE
